What is Nuclein?
Founded by Alan Blake and Dr. Richard Crockett, Nuclein operates at the intersection of biotechnology and point-of-care diagnostics. The company is dedicated to the development of a hand-held, disposable, all-in-one testing device designed to detect infectious diseases. By providing battery-powered, sample-to-answer results in under one hour, Nuclein effectively eliminates the logistical friction associated with traditional laboratory-based testing. This innovation positions the company as a disruptive force in the medical technology sector, addressing the critical need for rapid, decentralized diagnostic capabilities in both clinical and home-based environments.
How much funding has Nuclein raised?
Nuclein has raised a total of $20.9M across 3 funding rounds:
Series A
$5.6M
Series B
$14M
Debt
$1.3M
Series A (2020): $5.6M, investors not publicly disclosed
Series B (2021): $14M led by Trinity Private Equity Group
Debt (2026): $1.3M, investors not publicly disclosed
Key Investors in Nuclein
Trinity Private Equity Group
A private equity firm focused on growth-stage investments and strategic capital deployment across the healthcare and technology sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Nuclein?
With the successful acquisition of this latest capital, Nuclein is well-positioned to accelerate its operational scaling and product commercialization efforts. The strategic focus will likely shift toward optimizing manufacturing processes for its disposable testing units and navigating the complex regulatory landscape required for widespread market adoption. As the company transitions from a development-heavy entity to a commercial-stage enterprise, the focus on maintaining high-accuracy diagnostic standards while scaling production will be paramount. Investors and industry stakeholders will be monitoring the company's ability to integrate its technology into existing healthcare infrastructure, potentially setting a new standard for rapid infectious disease management.
See full Nuclein company page
